Scarica l'app Stockscreener
75.73
2.51%
-1.95
Dopo l'orario di chiusura:
76.50
0.77
+1.02%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PTGX Giù?
Forum
Previsione
Precedente Chiudi:
$77.68
Aprire:
$77.81
Volume 24 ore:
1.90M
Relative Volume:
1.82
Capitalizzazione di mercato:
$4.71B
Reddito:
$209.18M
Utile/perdita netta:
$52.04M
Rapporto P/E:
106.29
EPS:
0.7125
Flusso di cassa netto:
$37.10M
1 W Prestazione:
+12.96%
1M Prestazione:
+29.25%
6M Prestazione:
+65.35%
1 anno Prestazione:
+61.16%
Intervallo 1D:
$74.62
$78.00
Intervallo di 1 settimana:
$65.75
$93.25
Portata 52W:
$33.31
$93.25
Protagonist Therapeutics Inc Stock (PTGX) Company Profile
Nome
Protagonist Therapeutics Inc
Settore
Industria
Telefono
(510) 474-0170
Indirizzo
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
Confronta PTGX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PTGX
Protagonist Therapeutics Inc
|
75.73 | 4.79B | 209.18M | 52.04M | 37.10M | 0.7125 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-17 | Iniziato | Barclays | Overweight |
| 2025-09-12 | Iniziato | Leerink Partners | Outperform |
| 2025-06-17 | Iniziato | Citigroup | Buy |
| 2024-12-06 | Iniziato | BMO Capital Markets | Outperform |
| 2024-12-06 | Iniziato | Goldman | Neutral |
| 2024-11-05 | Iniziato | Wedbush | Outperform |
| 2024-09-24 | Iniziato | TD Cowen | Buy |
| 2024-09-09 | Iniziato | Truist | Buy |
| 2023-10-30 | Iniziato | CapitalOne | Overweight |
| 2023-05-25 | Ripresa | Jefferies | Buy |
| 2022-08-25 | Iniziato | JMP Securities | Mkt Outperform |
| 2022-02-11 | Iniziato | BTIG Research | Buy |
| 2021-10-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-10-11 | Aggiornamento | Northland Capital | Market Perform → Outperform |
| 2021-09-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-05-24 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-05-24 | Iniziato | Northland Capital | Outperform |
| 2021-01-06 | Iniziato | JP Morgan | Overweight |
| 2020-12-16 | Iniziato | Piper Sandler | Overweight |
| 2020-09-18 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-15 | Iniziato | Jefferies | Buy |
| 2020-05-18 | Reiterato | H.C. Wainwright | Buy |
| 2019-07-08 | Iniziato | H.C. Wainwright | Buy |
| 2019-05-09 | Aggiornamento | Stifel | Hold → Buy |
| 2018-12-06 | Iniziato | Nomura | Buy |
| 2018-01-29 | Iniziato | Stifel | Buy |
| 2017-07-21 | Iniziato | BTIG Research | Buy |
Mostra tutto
Protagonist Therapeutics Inc Borsa (PTGX) Ultime notizie
News impact scoring models applied to Protagonist Therapeutics Inc.July 2025 Outlook & Stepwise Trade Signal Implementation - newser.com
Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025 - Green Bay Press-Gazette
Is Protagonist Therapeutics Inc. a candidate for recovery playMarket Trend Review & Smart Swing Trading Alerts - newser.com
How Protagonist Therapeutics Inc. stock reacts to job market dataPortfolio Performance Report & Daily Volume Surge Trade Alerts - newser.com
How Protagonist Therapeutics Inc. stock responds to policy changes2025 Top Decliners & Safe Capital Growth Tips - newser.com
Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in September 2025 - FinancialContent
This 2.7%-Yielding Dividend King Remains One of the Healthiest Income Stocks You Can Buy - The Motley Fool
Predicting Protagonist Therapeutics Inc. trend using moving averagesMarket Trend Review & Safe Capital Preservation Plans - newser.com
Protagonist Therapeutics Stock Gains 30% as J&J Reportedly Eyes Deal - Zacks Investment Research
Johnson & Johnson Eyes Protagonist Therapeutics Acquisition, PTG - GuruFocus
Protagonist Therapeutics falls amid a report J&J deal price may be lower (PTGX:NASDAQ) - Seeking Alpha
J&J Could Be Latest Protagonist In M&A Merry-Go-Round - insights.citeline.com
Why Johnson & Johnson Is Eyeing Protagonist Therapeutics: The Rationale (NASDAQ:PTGX) - Seeking Alpha
Protagonist Therapeutics Reaches Analyst Target Price - Nasdaq
J&J in talks to acquire Protagonist Therapeutics - Yahoo Finance
Protagonist Therapeutics stock price target raised to $112 by BMO Capital - Investing.com Canada
Protagonist Therapeutics, Inc. $PTGX Stock Position Cut by Inspire Investing LLC - MarketBeat
Using data models to predict Protagonist Therapeutics Inc. stock movementQuarterly Profit Review & Daily Price Action Insights - newser.com
Johnson & Johnson To Acquire Protagonist? It'd Be A Good Deal To Make - Seeking Alpha
Protagonist Announces New Icotrokinra Data in Ulcerative Colitis Showing Potential for a Standout Combination of Therapeutic Benefit and a Favorable Safety Profile in Once-daily Pill - Pensacola News Journal
Protagonist Therapeutics (PTGX) Surges on Johnson & Johnson Acqu - GuruFocus
Key deals this week: Protagonist Therapeutics, Bristol Myers, Novo Nordisk, Fifth Third Bancorp and more - Seeking Alpha
Why Protagonist Therapeutics Stock Skyrocketed by Almost 30% Today - sharewise.com
Protagonist Therapeutics (NASDAQ:PTGX) Stock Price Up 9.4%What's Next? - MarketBeat
Protagonist Therapeutics: Small Biotech Skyrockets on Buyout Buzz & Breakthrough Trials - ts2.tech
Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) 51% Price Boost Is Out Of Tune With Revenues - simplywall.st
Protagonist Therapeutics (NASDAQ:PTGX) Sets New 12-Month HighHere's What Happened - MarketBeat
Protagonist Therapeutics Inc. (PTGX) Stock Price | Live Quotes & Charts | NSD - StocksToTrade
Protagonist Stock Surges on Johnson & Johnson Report - The Wall Street Journal
Pharma, Battery, And Biotech Stocks See Sudden Price Jumps - Finimize
Protagonist Therapeutics (PTGX) Surges on Takeover Speculation - GuruFocus
Johnson & Johnson in talks to acquire Protagonist Therapeutics, source says - WSAU
Protagonist Therapeutics Stock Notable Surge - timothysykes.com
Protagonist Therapeutics’s Recent Commendable Performance - StocksToTrade
Protagonist Therapeutics stock reaches all-time high at 73.34 USD By Investing.com - Investing.com Nigeria
Sudden Surge: PTGX’s Momentous Journey - timothysykes.com
Protagonist Therapeutics (PTGX) Skyrockets on J&J Buyout Buzz Amid Clinical Breakthroughs - ts2.tech
Protagonist Therapeutics stock reaches all-time high at 73.34 USD - Investing.com
Protagonist Therapeutics Sees Surging Stock Price: What’s Driving This? - StocksToTrade
Why Did Protagonist Therapeutics Stock Soar Today? - MSN
Johnson & Johnson In Talks To Acquire Protagonist Therapeutics: Report - Sahm
Protagonist Therapeutics Inc Azioni (PTGX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Protagonist Therapeutics Inc Azioni (PTGX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Waddill William D. | Director |
Oct 10 '25 |
Sale |
81.62 |
12,000 |
979,480 |
5,130 |
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):